terbinafine topical (OTC)

Brand and Other Names:Lamisil AT topical
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

cream/topical solution

  • 1%

Tinea Pedis

Apply to affected area BID until significant clinical improvement (no more than 4 weeks)

Tinea Corporis & Cruris

Apply qDay x1 week (no more than 4 weeks)

Not FDA approved for peds

Next:

Adverse Effects

1-10%

Burning

Contact dermatitis

Dryness

Exfoliation

Irritation

Pruritus

Rash

Irritation

Stinging

Previous
Next:

Warnings

Contraindications

Hypersensitivity

Not for oral, intravaginal, ophthalmic use

Previous
Next:

Pregnancy & Lactation

Pregnancy Category: B

Lactation: not safe for nursing infants

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Previous
Next:

Pharmacology

Metabolism: liver

Excretion: urine

Mechanism of Action

Inhibits squalene epoxidase, reducing cell membrane ergosterol synthesis

Previous
Next:

Images

Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.